Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunomodulatory Properties of Ketamine in Sepsis
NCT01089361Phase 2Completed
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Dec 2009
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ketamine in sepsis, sponsored by Beth Israel Deaconess Medical Center. Started Dec 2009; status: completed.
02
Drugs
ketamine
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT01089361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01089361.